Roche and PerkinElmer Enter into New Agreement for Distribution of NimbleGen CGX Cytogenetics Array Workflow
Madison, WI, USA, and Waltham, MA, USA, 18 August 2011
Roche (SIX: RO, ROG; OTCQX: RHHBY) and PerkinElmer (NYSE: PKI) today announced a new supply agreement for distribution of the NimbleGen CGX microarray workflow, for use in constitutional disease research. Under this agreement, effective January 2012, PerkinElmer will assume responsibility from Roche for sales, service, and support of the CGX array workflow for most countries outside of the U.S. Roche will continue to sell this innovative workflow in the U.S. and other select markets. This is a further evolution of the relationship between the two companies which started in 2009 with the development of a comprehensive cytogenetics array workflow.
The combined solution, the NimbleGen CGX array workflow, uses advanced microarray technologies from Roche with the cytogenetic-focused array design and analysis software developed from Signature Genomics (acquired by PerkinElmer in May 2010), which was the first laboratory to provide microarray-based cytogenetic testing in the U.S.
The workflow is a comprehensive microarray solution for the discovery and analysis of copy number variations associated with constitutional disorders for the cytogenetics research market. This optimized workflow consists of NimbleGen CGX microarrays, reagent kits, the NimbleGen Hybridization Systems, and Signature Genomics Genoglyphix® software for data analysis. The NimbleGen CGX array design was developed by Signature Genomics based on the analysis of over 50,000 cytogenetic samples to ensure appropriate coverage of the cytogenetically relevant regions. The arrays are available in multiple formats (3-, 6-, and 12-plex) to match the throughput requirements of the researcher.
According to Jim Corbett, President, Diagnostics, PerkinElmer, “We are delighted to continue our collaboration with Roche in helping to bring the benefits of a proven cytogenetics-based solution to researchers of new diagnostics outside of the US. We look forward to providing these diagnostics researchers with high-resolution, scalable and easy to use workflows to help them unlock DNA-based complexities of critical disease states.”
“This collaboration provides cytogenetics laboratories an array workflow with robust data, a quick and easy workflow, and powerful analysis tools,” stated Frank Pitzer, CEO of Roche NimbleGen. “PerkinElmer’s global experience in the genetic screening market and expertise in the field of cytogenetics is an ideal match for Roche NimbleGen’s innovative array technologies.”
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For more information about Roche NimbleGen, please visit www.nimblegen.com.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
GENOGLYPHIX is a trademark of Signature Genomics
All other product names and trademarks are the property of their respective owners.